Back to Search Start Over

Plug and play virus-like particles for the generation of anti-toxin antibodies.

Authors :
Edge RJ
Marriott AE
Stars EL
Patel RN
Wilkinson MC
King LDW
Slagboom J
Tan CH
Ratanabanangkoon K
Draper SJ
Ainsworth S
Source :
Toxicon: X [Toxicon X] 2024 Aug 26; Vol. 23, pp. 100204. Date of Electronic Publication: 2024 Aug 26 (Print Publication: 2024).
Publication Year :
2024

Abstract

Snakebite is a major global health concern, for which antivenom remains the only approved treatment to neutralise the harmful effects of the toxins. However, some medically important toxins are poorly immunogenic, resulting in reduced efficacy of the final product. Boosting the immunogenicity of these toxins in the commercial antivenom immunising mixtures could be an effective strategy to improve the final dose efficacy, and displaying snake antigens on Virus-like particles (VLPs) is one method for this. However, despite some applications in the field of snakebite, VLPs have yet to be explored in methods that could be practical at an antivenom manufacturing scale. Here we describe the utilisation of a "plug and play" VLP system to display immunogenic linear peptide epitopes from three finger toxins (3FTxs) and generate anti-toxin antibodies. Rabbits were immunised with VLPs displaying individual consensus linear epitopes and their antibody responses were characterised by immunoassay. Of the three experimental consensus sequences, two produced antibodies capable of recognising the consensus peptides, whilst only one of these could also recognise native whole toxins. Further characterisation of antibodies raised against this peptide demonstrated a sub-class specific response, and that these were able to elicit partially neutralising antibody responses, resulting in increased survival times in a murine snakebite envenoming model.<br />Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Simon J Draper reports a relationship with SpyBiotech that includes: board membership and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2024 The Authors.)

Details

Language :
English
ISSN :
2590-1710
Volume :
23
Database :
MEDLINE
Journal :
Toxicon: X
Publication Type :
Academic Journal
Accession number :
39280983
Full Text :
https://doi.org/10.1016/j.toxcx.2024.100204